Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
QuantumPharm, Inc. ( (HK:2228) ) has provided an announcement.
XtalPi Holdings Limited has granted 11,234,290 share options to 137 employees and 10,920,770 restricted share units to 270 employees under its existing equity incentive schemes, with all awards subject to acceptance. The move, which excludes directors, chief executives and substantial shareholders, is designed to motivate staff and align employee interests with the group’s long-term operational development and strategic growth, using a five-year exercise period and staggered vesting over up to 36 months.
The share options are exercisable at HK$9.61, matching the closing share price on the April 9, 2026 grant date and set in accordance with listing rules that require pricing at or above recent market levels. The remuneration committee and board argue that allowing part of the options to vest in under 12 months, within an overall 36‑month schedule, appropriately balances retention and incentive goals, potentially strengthening XtalPi’s ability to attract and retain key talent in a competitive market.
The most recent analyst rating on (HK:2228) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
XtalPi Holdings Limited is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange. The group operates through multiple subsidiaries and employs a broad base of staff across its operations, though no directors, chief executives or substantial shareholders are included in the latest incentive grants.
Average Trading Volume: 69,544,073
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.8B
Find detailed analytics on 2228 stock on TipRanks’ Stock Analysis page.